tradingkey.logo

Aligos Therapeutics Inc <ALGS.OQ> expected to post a loss of $2.80 a share - Earnings Preview

ReutersMay 2, 2025 12:59 PM
  • Aligos Therapeutics Inc ALGS.OQ ALGS.O is expected to show a fall in quarterly revenue when it reports results on May 6 for the period ending March 31 2025

  • The South San Francisco California-based company is expected to report a 66.2% decrease in revenue to $333.33 thousand from $986 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Aligos Therapeutics Inc is for a loss of $2.80 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aligos Therapeutics Inc is $70.00​, above​ its last closing price of $6.04. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-2.50

-3.40

Missed

-36.2

Sep. 30 2024

-2.47

-2.16

-3.07

Missed

-42.3

Jun. 30 2024

-4.00

-4.00

0.80

Beat

120​

Mar. 31 2024

-4.75

-4.75

-5.50

Missed

-15.8

​​Dec. 31 2023

-2.75

-6.75

-5.50

Beat

18.5

Sep. 30 2023

-11.73

-11.87

-10.25

Beat

13.7​

Jun. 30 2023

-12.19

-12.37

-10.75

Beat

13.1

Mar. 31 2023

-11.93

-12.12

-13.25

Missed

-9.3

This summary was machine generated May 2 at 12:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI